Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Apropå! Immunitet mot mässling.

Hallander HO, Ljungman M.

Lakartidningen. 2018 Feb 2;115. pii: EZSZ. Swedish. No abstract available.

2.

[New whooping cough deaths].

Hallander HO.

Lakartidningen. 2016 Mar 21;113. pii: DYHY. Swedish. No abstract available.

3.
4.

[Whooping cough--time to reconsider the vaccination program].

Hallander HO.

Lakartidningen. 2015 Jun 23;112. pii: DI6X. Swedish. No abstract available.

5.

Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.

Carlsson RM, Gustafsson L, Hallander HO, Ljungman M, Olin P, Gothefors L, Nilsson L, Netterlid E.

Vaccine. 2015 Jul 17;33(31):3717-25. doi: 10.1016/j.vaccine.2015.05.079. Epub 2015 Jun 7.

PMID:
26057135
6.

Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012.

van Gent M, Heuvelman CJ, van der Heide HG, Hallander HO, Advani A, Guiso N, Wirsing von Kőnig CH, Vestrheim DF, Dalby T, Fry NK, Pierard D, Detemmerman L, Zavadilova J, Fabianova K, Logan C, Habington A, Byrne M, Lutyńska A, Mosiej E, Pelaz C, Gröndahl-Yli-Hannuksela K, Barkoff AM, Mertsola J, Economopoulou A, He Q, Mooi FR.

Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):821-30. doi: 10.1007/s10096-014-2297-2. Epub 2014 Dec 20.

7.

Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.

Zeddeman A, van Gent M, Heuvelman CJ, van der Heide HG, Bart MJ, Advani A, Hallander HO, Wirsing von Konig CH, Riffelman M, Storsaeter J, Vestrheim DF, Dalby T, Krogfelt KA, Fry NK, Barkoff AM, Mertsola J, He Q, Mooi F.

Euro Surveill. 2014 Aug 21;19(33). pii: 20881.

8.

Modeling rates of infection with transient maternal antibodies and waning active immunity: application to Bordetella pertussis in Sweden.

Feng Z, Glasser JW, Hill AN, Franko MA, Carlsson RM, Hallander H, Tüll P, Olin P.

J Theor Biol. 2014 Sep 7;356:123-32. doi: 10.1016/j.jtbi.2014.04.020. Epub 2014 Apr 23.

PMID:
24768867
9.

Global population structure and evolution of Bordetella pertussis and their relationship with vaccination.

Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, Bouchez V, Cassiday PK, Chiang CS, Dalby T, Fry NK, Gaillard ME, van Gent M, Guiso N, Hallander HO, Harvill ET, He Q, van der Heide HG, Heuvelman K, Hozbor DF, Kamachi K, Karataev GI, Lan R, Lutyńska A, Maharjan RP, Mertsola J, Miyamura T, Octavia S, Preston A, Quail MA, Sintchenko V, Stefanelli P, Tondella ML, Tsang RS, Xu Y, Yao SM, Zhang S, Parkhill J, Mooi FR.

mBio. 2014 Apr 22;5(2):e01074. doi: 10.1128/mBio.01074-14.

10.

Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007.

Hallander H, Advani A, Alexander F, Gustafsson L, Ljungman M, Pratt C, Hall I, Gorringe AR.

Clin Vaccine Immunol. 2014 Feb;21(2):165-73. doi: 10.1128/CVI.00641-13. Epub 2013 Dec 4.

11.

Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009.

Advani A, Hallander HO, Dalby T, Krogfelt KA, Guiso N, Njamkepo E, von Könnig CH, Riffelmann M, Mooi FR, Sandven P, Lutynska A, Fry NK, Mertsola J, He Q.

J Clin Microbiol. 2013 Feb;51(2):422-8. doi: 10.1128/JCM.02036-12. Epub 2012 Nov 21.

12.

[The Swedish child vaccination program also reaches the children born abroad. Serologic samples show good protection compared to Swedish-born].

Andersson MA, Hallander H, Ljungman M, Norder H, Brytting M, Thorstensson R, Netterlid E.

Lakartidningen. 2012 Jan 18-24;109(3):94-8. Swedish. No abstract available.

PMID:
22448560
13.

Is adolescent pertussis vaccination preferable to natural booster infections?

Hallander HO, Nilsson L, Gustafsson L.

Expert Rev Clin Pharmacol. 2011 Nov;4(6):705-11. doi: 10.1586/ecp.11.55. Review.

PMID:
22111856
14.

Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: analyses of 10 years of pertussis surveillance.

Nilsson L, Lepp T, von Segebaden K, Hallander H, Gustafsson L.

Vaccine. 2012 May 2;30(21):3239-47. doi: 10.1016/j.vaccine.2011.10.089. Epub 2011 Nov 15.

PMID:
22094282
15.

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.

Borrow R, Dagan R, Zepp F, Hallander H, Poolman J.

Expert Rev Vaccines. 2011 Nov;10(11):1621-31. doi: 10.1586/erv.11.142. Review.

PMID:
22043960
16.

Pertussis vaccines: where to now?

Poolman JT, Hallander H, Halperin SA.

Expert Rev Vaccines. 2011 Nov;10(11):1497-500. doi: 10.1586/erv.11.147. No abstract available.

PMID:
22043947
17.

SNP-based typing: a useful tool to study Bordetella pertussis populations.

van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Kallonen T, He Q, Mertsola J, Advani A, Hallander HO, Janssens K, Hermans PW, Mooi FR.

PLoS One. 2011;6(5):e20340. doi: 10.1371/journal.pone.0020340. Epub 2011 May 27.

18.

Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs.

Advani A, Gustafsson L, Ahrén C, Mooi FR, Hallander HO.

Vaccine. 2011 Apr 18;29(18):3438-42. doi: 10.1016/j.vaccine.2011.02.070. Epub 2011 Mar 9.

PMID:
21396900
19.

Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease.

Hallander HO, Lepp T, Ljungman M, Netterlid E, Andersson M.

APMIS. 2010 Nov;118(11):878-87. doi: 10.1111/j.1600-0463.2010.02674.x. Epub 2010 Sep 2.

PMID:
20955461
20.

Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.

Cherry JD, Heininger U, Richards DM, Storsaeter J, Gustafsson L, Ljungman M, Hallander HO.

Clin Vaccine Immunol. 2010 May;17(5):741-7. doi: 10.1128/CVI.00469-09. Epub 2010 Mar 24.

21.

Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program.

Hallander HO, Andersson M, Gustafsson L, Ljungman M, Netterlid E.

APMIS. 2009 Dec;117(12):912-22. doi: 10.1111/j.1600-0463.2009.02554.x.

22.

[Good immune response of diphtheria-tetanus-pertussis vaccination in the 4th grade. Local reaction very common--and expected].

Nilsson L, Carlsson RM, Hallander HO, Ljungman M, Hallberg M, Storsaeter J.

Lakartidningen. 2009 Sep 16-22;106(38):2357-61. Swedish. No abstract available.

PMID:
19848341
23.

Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.

Hallander HO, Ljungman M, Storsaeter J, Gustafsson L.

APMIS. 2009 Nov;117(11):797-807. doi: 10.1111/j.1600-0463.2009.02530.x.

PMID:
19845530
24.

Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience.

Hallander HO, Gustafsson L.

Expert Rev Vaccines. 2009 Oct;8(10):1303-7. doi: 10.1586/erv.09.88. No abstract available.

PMID:
19803750
25.

Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.

Hallander HO, Ljungman M, Jahnmatz M, Storsaeter J, Nilsson L, Gustafsson L.

APMIS. 2009 Sep;117(9):660-71. doi: 10.1111/j.1600-0463.2009.02521.x.

PMID:
19703126
26.

Analysis of Swedish Bordetella pertussis isolates with three typing methods: characterization of an epidemic lineage.

Advani A, Van der Heide HG, Hallander HO, Mooi FR.

J Microbiol Methods. 2009 Sep;78(3):297-301. doi: 10.1016/j.mimet.2009.06.019. Epub 2009 Jul 3.

PMID:
19577594
27.

European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations.

Giammanco A, Nardone A, Pebody R, Kafatos G, Andrews N, Chiarini A, Taormina S, de Ory F, Prosenc K, Krize B, Hallander H, Ljungman M, Marva E, Tsakris A, O'Flanagan D, Schneider F, Griskevicius A, Vranckx R, Karacs I.

Vaccine. 2008 Aug 18;26(35):4486-93. doi: 10.1016/j.vaccine.2008.06.051. Epub 2008 Jul 3.

PMID:
18602434
28.

Performance of Bordetella pertussis IS481 real-time PCR in a vaccine trial setting.

Gullsby K, Hallander HO, Bondeson K.

APMIS. 2007 Dec;115(12):1370-5. doi: 10.1111/j.1600-0463.2007.00774.x.

PMID:
18184407
29.

Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis.

Hallander H, Advani A, Riffelmann M, von König CH, Caro V, Guiso N, Mooi FR, Gzyl A, Kaltoft MS, Fry NK, Mertsola J, He Q.

J Clin Microbiol. 2007 Oct;45(10):3257-62. Epub 2007 Aug 15.

30.

Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype.

Advani A, Gustafsson L, Carlsson RM, Donnelly D, Hallander HO.

APMIS. 2007 Jun;115(6):736-42.

PMID:
17550382
31.
32.

Acellular pertussis vaccines and the role of pertactin and fimbriae.

Poolman JT, Hallander HO.

Expert Rev Vaccines. 2007 Feb;6(1):47-56. Review.

PMID:
17280478
33.

Shifts of rotavirus g and p types in Nicaragua--2001-2003.

Espinoza F, Bucardo F, Paniagua M, Svensson L, Hallander HO, Bondeson K.

Pediatr Infect Dis J. 2006 Nov;25(11):1078-80.

PMID:
17072136
34.

Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories.

Elomaa A, Advani A, Donnelly D, Antila M, Mertsola J, He Q, Hallander H.

Vaccine. 2007 Jan 15;25(5):918-26. Epub 2006 Sep 20.

PMID:
17030495
35.

Comparison of real-time PCR and pyrosequencing for typing Bordetella pertussis toxin subunit 1 variants.

Storm M, Advani A, Pettersson M, Hallander HO, Bondeson K.

J Microbiol Methods. 2006 Apr;65(1):153-8. Epub 2005 Aug 10.

PMID:
16095736
36.

Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years.

Elomaa A, Advani A, Donnelly D, Antila M, Mertsola J, Hallander H, He Q.

J Clin Microbiol. 2005 Aug;43(8):3681-7.

37.

Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.

Denoël P, Godfroid F, Guiso N, Hallander H, Poolman J.

Vaccine. 2005 Nov 16;23(46-47):5333-41. Epub 2005 Jul 11.

PMID:
16054273
38.

Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose.

Hallander HO, Gustafsson L, Ljungman M, Storsaeter J.

Vaccine. 2005 Nov 16;23(46-47):5359-64. Epub 2005 Jul 1.

PMID:
16051400
39.

Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies.

Caro V, Njamkepo E, Van Amersfoorth SC, Mooi FR, Advani A, Hallander HO, He Q, Mertsola J, Riffelmann M, Vahrenholz C, Von König CH, Guiso N.

Microbes Infect. 2005 Jun;7(7-8):976-82.

PMID:
15994109
40.

Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.

Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM.

J Clin Microbiol. 2005 Jun;43(6):2856-65.

41.

Analysis of Bordetella pertussis populations in European countries with different vaccination policies.

van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hallander HO, Bondeson K, von König CH, Riffelmann M, Vahrenholz C, Guiso N, Caro V, Njamkepo E, He Q, Mertsola J, Mooi FR.

J Clin Microbiol. 2005 Jun;43(6):2837-43.

43.
44.
45.

Legionella pneumophila serogroup 1 antibody kinetics in patients with Legionnaires' disease: implications for serological diagnosis.

Darelid J, Löfgren S, Malmvall BE, Olinder-Nielsen MA, Briheim G, Hallander H.

Scand J Infect Dis. 2003;35(1):15-20.

PMID:
12685878
46.

Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden.

Olin P, Hallander HO.

Euro Surveill. 1999 Dec;4(12):128-129.

PMID:
12631878
47.

Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.

Hallander HO, Paniagua M, Espinoza F, Askelöf P, Corrales E, Ringman M, Storsaeter J.

Vaccine. 2002 Nov 22;21(1-2):138-45.

PMID:
12443672
48.

Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine.

Obaro SK, Enwere GC, Deloria M, Jaffar S, Goldblatt D, Brainsby K, Hallander H, McInnes P, Greenwood BM, McAdam KP.

Pediatr Infect Dis J. 2002 Oct;21(10):940-7.

PMID:
12394817
49.

How to make sense of pertussis immunogenicity data.

Olin P, Hallander HO, Gustafsson L, Reizenstein E, Storsaeter J.

Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S288-91. Review.

PMID:
11709761
50.

Supplemental Content

Loading ...
Support Center